Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 8/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 7/20 | 0.33 |
| ▸ | CES2 | O00748 | 2/20 | 0.32 |
| ▸ | CES1 | P23141 | 2/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102980 | 0.86 | CA12 (0.34) | CA12CA9ALDH1A1 | |
| SCHEMBL103877 | 0.85 | ALDH1A1 (0.40) | CA12CA1CA9ALDH1A1MMP1 | |
| SCHEMBL103667 | 0.80 | CA12 (0.40) | CA12CA1CA9ALDH1A1MMP1 | |
| SCHEMBL3502037 | 0.78 | CA1 (0.39) | CA12CA1CA9ALDH1A1MMP1 | |
| SCHEMBL31462921 | 0.78 | CA12 (0.35) | CA12CA1CA9ALDH1A1MMP1 | |
| SCHEMBL103879 | 0.77 | ALDH1A1 (0.50) | CA1ALDH1A1KDM5AKDM4CCES2 | |
| SCHEMBL102982 | 0.77 | — | — | |
| SCHEMBL29882148 | 0.76 | CYP1A2 (0.46) | ALDH1A1KDM5AKDM4C | |
| SCHEMBL8521291 | 0.72 | DNM1 (0.34) | CA12CA1CA9CES2CES1 | |
| SCHEMBL30442978 | 0.72 | CA12 (0.44) | CA12CA1CA9ALDH1A1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8728442-B2 | Method of controlling the growth of microorganisms by a composition containing isolated or in vitro synthesized nitrosoamides | BAYER CROPSCIENCE LP (US) | 2014-05-20 | — | — | US | disclosed |
| US-8728442-B2 | Method of controlling the growth of microorganisms by a composition containing isolated or in vitro synthesized nitrosoamides | BAYER CROPSCIENCE LP (US) | 2014-05-20 | — | — | US | disclosed |
| US-20120058058-A1 | COMPOUNDS DERIVED FROM MUSCODOR FUNGI | AGRAQUEST, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058058-A1 | COMPOUNDS DERIVED FROM MUSCODOR FUNGI | AGRAQUEST, INC. (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058058-A1 | COMPOUNDS DERIVED FROM MUSCODOR FUNGI | SPOUT1, ERG28, DDT | CA12 4498/4885CA1 3779/4885CA9 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.